TWi Pharmaceuticals, Takeda arguments draw skepticism from US judge
Litigation accusing TWi Pharmaceuticals and Takeda Pharmaceutical Co. of conspiring to restrain competition in the market for heartburn medication Dexilant and its generic equivalents is likely to move forward, a US...To view the full article, register now.
Already a subscriber? Click here to view full article